Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Antiparasitic activity of nerolidol in a mouse model of schistosomiasis

Full text
Author(s):
Show less -
Silva, Marcos P. [1] ; de Oliveira, Rosimeire N. [2] ; Mengarda, Ana C. [1] ; Roquini, Daniel B. [1] ; Allegretti, Silmara M. [2] ; Salvadori, Maria C. [3] ; Teixeira, Fernanda S. [3] ; de Sousa, Damiao P. [4] ; Pinto, Pedro L. S. [5] ; da Silva Filho, Ademar A. [6] ; de Moraes, Josue [1]
Total Authors: 11
Affiliation:
[1] Univ Guarulhos, Nucl Pesquisa Doencas Negligenciadas, Praca Tereza Cristina 229, BR-07023070 Guarulhos - Brazil
[2] Univ Estadual Campinas, Inst Biol, Dept Biol Anim, Campinas, SP - Brazil
[3] Univ Sao Paulo, Inst Fis, Sao Paulo, SP - Brazil
[4] Univ Fed Paraiba, Dept Ciencias, Joao Pessoa, Paraiba - Brazil
[5] Adolfo Lutz Inst, Nucl Enteroparasitas, Sao Paulo, SP - Brazil
[6] Univ Fed Juiz de Fora, Fac Farm, Dept Ciencias Farmaceut, Juiz De Fora, MG - Brazil
Total Affiliations: 6
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS; v. 50, n. 3, p. 467-472, SEP 2017.
Web of Science Citations: 11
Abstract

Schistosomiasis is a major public health problem worldwide, especially in poor communities. Since praziquantel is currently the only drug available to treat schistosomiasis, there is an urgent need to identify new antischistosomal drugs. Nerolidol is a sesquiterpene present as an essential oil in several plants that has been approved by the FDA. This study evaluated the in vivo antischistosomal activity of nerolidol in a mouse model of schistosomiasis infected with either adult or juvenile stages of Schisfosorito mansoul. A single dose of nerolidol (100,200 or 400 mg/kg) administered orally to mice infected with adult schistosomes resulted in a reduction in worm burden and egg production. Treatment with the highest nerolidol dose (400 mg/kg) caused significant reduction in a total worm burden of 70.06% (P < 0.001). Additionally, the technique of quantitative and qualitative oograms showed that a single 400 mg/kg nerolidol dose achieved an immature egg reduction of 34.6% (P < 0.001). In faecal samples, the Kato-Katz method also revealed a reduction of 75.2% in eggs/g at a dose of 400 mg/kg (P < 0,001). Furthermore, scanning electron microscopy revealed that nerolidol-mediated worm killing was associated with tegumental damage. In contrast to activity against adult S. rnansoni infection, oral treatment with nerolidol 400 mg/kg had low efficacy in mice harbouring juvenile schistosomes. Since nerolidol is already in use globally as a food additive and has a proven safety record, evaluation of this natural compound's potential for treatment of schistosomiasis could be entirely cost effective in the near future. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. (AU)

FAPESP's process: 16/22488-3 - Drug repositioning for neglected diseases: identification of novel anthelmintic agents
Grantee:Josué de Moraes
Support Opportunities: Regular Research Grants